摘要
弥漫大B细胞淋巴瘤(DLBCL)是最常见的非霍奇金淋巴瘤类型.目前的治疗方案能显著改善患者的预后,但30％～40％的DLBCL患者出现难治(耐药)或复发.对于难治/复发的DLBCL患者,临床上治疗仍困难,其预后不佳.异基因造血干细胞移植(allo-HSCT)仍是难治/复发DLBCL患者最重要的根治手段之一.本文就allo-HSCT治疗难治/复发DLBCL作用及其进展进行综述.
Abstract
Diffuse large B-cell lymphoma(DLBCL)is the most common type of non Hodgkin's lymphoma.The current treatment plan can significantly improve the prognosis of patients,but about 30％-40％of DLBCL patients still experience drug resistance and relapse after treatment.For patients with refractory/relapse DLBCL,clinical treatment remains difficult and their prognosis is poor.Allogeneic hematopoietic stem cell transplantation(allo-HSCT)remains one of the most important curative methods for refractory/relapse DLBCL patients.This article will review the role and progress of allo-HSCT in the treatment of refractory/relapse DLBCL.
NETL
NSTL
维普
万方数据